首页> 外文期刊>The Journal of Urology >Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial
【24h】

Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial

机译:用Axitinib治疗局部晚期透明细胞肾细胞癌新辅助治疗后肾肿瘤实心界面的研究:II期试验的匹配分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: The aim of this study was to evaluate histological changes in the tumorparenchymal interface in clear cell renal cell carcinoma after neoadjuvant axitinib treatment. Materials and Methods: We obtained clinical and pathology materials from 23 patients with clear cell renal cell carcinoma treated with neoadjuvant axitinib in a phase II clinical trial and from 23 matched patients with clear cell renal cell carcinoma who underwent upfront surgery. Histology of the tumor pseudocapsule and the peritumor kidney parenchymal change was evaluated and compared between the 2 cohorts. Results: A tumor pseudocapsule was noted in all 23 patients who received neoadjuvant axitinib and in all 23 control patients. Most pseudocapsules were noncontinuous and only partially covered the tumor, including in 17 of 23 axitinib cases (74%) and 19 of 23 controls (83%). In axitinib cases the median thickness of the intrarenal and extrarenal pseudocapsule was 1.4 and 2.4 mm, respectively, which was significantly thicker than in control cases (intrarenal p = 0.0008 and extrarenal p < 0.0001). The thickness of the pseudocapsule in axitinib treated cases was more frequently irregular compared to that in controls (16 of 23 or 70% and 9 of 23 or 39%, respectively, p = 0.0746). Inflammation, nephrosclerosis, glomerulosclerosis and arteriosclerosis decreased with increasing distance from the tumor edge in the neoadjuvant axitinib and control groups. Conclusions: The tumor pseudocapsule becomes irregularly thick after neoadjuvant axitinib therapy. Although axitinib likely evokes a strong fibrous reaction in the tumor-parenchymal interface, it does not affect the frequency of infiltrative tumor invasion to the outside of the pseudocapsule or the degree of atrophic/inflammatory change in tissue surrounding the tumor. These findings support the notion that partial
机译:目的:本研究的目的是在Neoadjuvant Axitinib治疗后评估透明细胞肾细胞癌中的肿瘤间界面的组织学变化。材料和方法:我们从第二阶段临床试验中使用Neoadjuvant Axitinib治疗的23例透明细胞肾细胞癌和23例患有23例患有前期手术的透明细胞肾细胞癌的23例临床和病理学材料获得临床和病理学材料。评估肿瘤假胶囊的组织学,并在2个队列之间进行了比较并比较了肿瘤肾上实质变化。结果:在所有23名接受Neoadjuvant Axitinib和所有23名对照患者的患者中注意到肿瘤假胶囊。大多数假胶囊是非连续的,仅部分覆盖肿瘤,包括在23例中的17例(74%)和23例中的19例(83%)中。在Axitinib病例中,内部和外部假胶囊的中值分别为1.4和2.4mm,显着比对照案例显着厚(Intrarenal P = 0.0008和外肠P <0.0001)。与对照中的对照(分别为23或70%,共23%,p = 0.0746,p = 0.0746的对照相比,Axitinib处理病例中的假胶质腐植物的厚度更频繁地是不规则的。炎症,肾粥样硬化,肾小球粥样硬化和动脉硬化随着Neoadjuvant Axitinib和对照组中的肿瘤边缘的距离而降低。结论:肿瘤假胶囊在Neoadjuvant Axitinib治疗后不规则厚。尽管Axitinib可能在肿瘤实质界面中唤起强烈的纤维反应,但它不会影响渗透肿瘤侵袭到假胶囊外部的频率或肿瘤周围组织中的萎缩/炎症变化程度。这些调查结果支持部分的概念

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号